| Serial Number | 79359336 |
| Word Mark | EVOX THERAPEUTICS |
| Filing Date | Thursday, December 1, 2022 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, January 21, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 21, 2025 |
| Goods and Services | Pharmaceuticals, namely, drug delivery agents in the form of exosomes consisting of compounds that facilitate the delivery of a wide range of pharmaceutical preparations; pharmaceutical preparations, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use, namely, for the release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, engineered exosomes to deliver pharmaceutical preparations in the nature of protein for genetic therapy; medicine, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; medical preparations, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; biological preparations for medical purposes, namely, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; biological preparations comprising exosomes, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations comprising a therapeutic target protein-loaded exosome that facilitates the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations comprising exosomes for pharmaceutical purposes that facilitate the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological reagents for medical use, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; mixed biological preparations for medical purposes, namely, for the prevention and treatment of infectious diseases; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, extracellular vesicle (EV)-based nucleic acid therapeutics for the prevention and treatment of infections or infectious diseases; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies, namely, mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; all of the foregoing excluding such goods in the fields of digestive diseases, gastrointestinal diseases, constipation, gut health, weight loss, appetite suppressants, dietetic preparations, nutrition, and enzymes |
| NOT AVAILABLE | "THERAPEUTICS" |
| Goods and Services | Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific research and analysis services in the field of pharmaceuticals; biological research; clinical research in the field of transformational therapeutics; providing medical research and scientific research information in the field of filtration of exosomes from blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of infectious diseases and metabolic disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; all of the foregoing excluding such services in the fields of digestive diseases, gastrointestinal diseases, constipation, gut health, weight loss, appetite suppressants, dietetic preparations, nutrition, and enzymes |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 3, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 3, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Evox Therapeutics Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Evox Therapeutics Limited |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Evox Therapeutics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Tuesday, January 3, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, December 30, 2022 | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB |
| Saturday, January 7, 2023 | APPLICATION FILING RECEIPT MAILED |
| Monday, September 11, 2023 | ASSIGNED TO EXAMINER |
| Saturday, September 23, 2023 | NON-FINAL ACTION WRITTEN |
| Sunday, September 24, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, October 4, 2023 | REFUSAL PROCESSED BY MPU |
| Thursday, October 5, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Thursday, April 4, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, April 4, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, April 6, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, October 31, 2023 | REFUSAL PROCESSED BY IB |
| Monday, November 27, 2023 | CORRECTION SENT TO IB |
| Monday, November 27, 2023 | CORRECTION CREATED FOR IB |
| Tuesday, May 14, 2024 | ASSIGNED TO EXAMINER |
| Friday, June 7, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Thursday, June 20, 2024 | FINAL REFUSAL WRITTEN |
| Thursday, June 20, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Monday, November 25, 2024 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Friday, December 20, 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Friday, December 20, 2024 | EXPARTE APPEAL RECEIVED AT TTAB |
| Friday, December 20, 2024 | EX PARTE APPEAL-INSTITUTED |
| Friday, December 20, 2024 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Thursday, June 20, 2024 | FINAL REFUSAL E-MAILED |
| Monday, December 23, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, December 23, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, December 23, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, December 26, 2024 | EXPARTE APPEAL TERMINATED |
| Wednesday, January 15, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 21, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, January 21, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |